A Tale of the Three Banks Earnings
If you’ve been watching the Singapore market this past month, the narrative has been impossible to ignore: it is a tale of three banks, and unfortunately for UOB, it has found itself lagging its peers.
The main theme of the month’s SRS Fund update is the strategic reduction of my UOB position. Following a quarterly result that was the softest of the trio, UOB shares have experienced some weakness while DBS and OCBC continued to perform strongly
Consequently, I made the decision to reduce the SRS Fund’s UOB holding by 50%, rotating the proceeds into a high-conviction tech turnaround play: AEM Holdings.
The UOB Weakness: Why I Trimmed the Position
The market response to UOB’s earnings has been tepid, and given the comparative strength of its peers, I felt it was prudent to reallocate capital.
First, there was the loss provision. While its rivals are basking in clean balance sheets and holding reserves steady, UOB provided significant provisions in its earnings. While this may be a prudent move by management, the immediate market reaction has been negative, resulting in share price weakness that cannot be ignored.
Second, and perhaps more concerning, is the wealth management divergence. In a golden era for Asian wealth management, UOB’s income from this segment failed to grow as strongly as its rivals. Compared to the double-digit momentum seen in DBS, UOB’s growth looked more modest.
As a result, I have reduced the SRS Fund’s allocation to 5.9% effectively halving the fund’s exposure to manage opportunity cost while still retaining a position for potential longer-term recovery.
The Pivot: Doubling Down on AEM (5.9%)
The funds released from the UOB sale were immediately redeployed into AEM Holdings, bringing its weight in the portfolio to 5.9% – now equal to the UOB stake.
Why AEM? The thesis is to capitalise on two converging tailwinds:
- The Intel Turnaround : AEM’s fortunes have long been tied to its key customer, Intel. With Intel’s aggressive cost-cutting and strategic pivot finally gaining traction in 2025, there are definately green shoots of a genuine turnaround with its Malaysian new CEO. As Intel stabilises, AEM stabilises.
- Massive AI Chip Order Volume: The demand for testing services is skyrocketing, driven by the increasing volume of next-generation AI chips entering the market. AEM’s test handlers are critical for these complex, high-performance chips. The company recently reported a 16% rise in Q3 revenue and a staggering 592% jump in profit before tax, proving that the “AI/HPC ramp” is not just a buzzword but is showing up in the bottom line.

Portfolio Resilience: The “DBS Shield”
Despite the weakness in UOB, I am pleased to report that the SRS Fund is up 22.6% YTD, hitting a fresh high of $576,590.
The Heavyweight Hero (DBS @ 23.5%). As shown in the chart above, my conviction in DBS has paid off. At 23.5% of the portfolio, DBS is doing the heavy lifting. Its earnings beat and dominant wealth management franchise have effectively acted as a shield, buffering the portfolio against the UOB dip.
Portfolio Segments

With the trimming of UOB, the SRS Fund has reduced its focus on the finance sector from 43% to 37.1%. Reducing exposure to the finance segment also gives the SRS Fund a more balanced concentration, diversifying risk.
Dividends

Q4 is off to a quiter start on the dividend front with $2,887.52 worth of collection compared to the massive Q2 & Q3 payout saw earlier in the year. This seasonality is expected, but the steady flow of income continues to anchor total return.
SRS Fund Value

Total SRS Fund value hit another record high at $576,590. I wouldn’t write off the $600k mark just yet with still another month to go and pending this year contributions.
Cash Levels

With the proceeds from the selling of UOB shares cash level now stands at 4.1% allowing me to add to any opportunities that arise in the following few months.
Summary
The trimming of UOB was a necessary rotation as I aim to keep the SRS Fund’s capital working efficiently. By halving the UOB position and rotating into AEM, I have swapped a slower-moving bank allocation for a recovery tech play with a strong AI tailwind.


-

The SRS Fund Dec 2025
If someone had told me at the start of the year that the Singapore stock market would deliver returns in excess of 20%, I would have shrugged it off as wishful thinking.
-

MyNest US Fund Dec 25
MyNest US Fund rounded the first year of inception with a slight outperformance to our benchmark the S&P 500. The first year of operation tested to resolve in knowing what we own as we navigated volatility which started on Trump’s Liberation Day.
-

The SRS Fund Nov 2025
If you’ve been watching the Singapore market this past month, the narrative has been impossible to ignore: it is a tale of three banks, and unfortunately for UOB, it has found itself lagging its peers.
-

MyNest US Fund Nov 25
November tested the patience of the broader market, defined by a distinct shift in sentiment regarding Artificial Intelligence. The narrative of an “AI Bubble” finally took hold,
-

The SRS Fund Oct 2025
Many of us in Singapore watch in dismay as interest rates from T-bills, fixed deposits and high-yield bank accounts plummet to new lows in recent months. Three months Sora now stands at 1.29%.
-

MyNest US Fund Oct 25
October is usually the worst month of the year for stocks but somehow this year the stock market failed to provide any opportunities for us to deploy meaningful cash to work.
